MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1241 in Combination with Efruxifermin Shows Enhanced ...

(Nasdaq:MODD) has shared new data highlighting the use of its insulin pump technology to deliver GLP-1 therapeutics.

Poster Presentation – “Nimacimab, a Peripherally Restricted CB1 Inhibitor, Promotes Metabolic Homeostasis in a Diet-Induced Obesity (DIO) Mouse Model as Demonstrated by Weight Loss, Restored Hormonal ...

Diabetes affects the body’s ability to control glucose, often causing excess glucose to build up in the bloodstream. Staph feeds off these high sugar levels, allowing it to reproduce more rapidly.

These drugs, which mimic the gut hormone glucagon-like peptide-1 (GLP-1), can help treat those with type 2 diabetes by stimulating the production of insulin and improving the function of beta cells.

Tests in mouse models of diabetes suggests that an experimental drug could help 'regrow' insulin-producing beta cells, thereby reversing the disease. Medical News Today Health Conditions ...

SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous ...

In a recent study posted to bioRxiv*, researchers in the United States assessed the impact of metabolic diseases on coronavirus disease 2019 (COVID-19) vaccine immunogenicity in a mouse model.

Scientists at the University of Texas (UT) Southwestern have demonstrated how restoring this delicate balance can cure the disease in mouse models, by essentially converting one type of cell into ...

The team tested the treatment in a mouse model of diabetes. Sure enough, the 5MCAR T cells successfully attacked and destroyed the animals’ autoimmune CD4+ T cells, mitigating their diabetes.

Type 1 diabetes, or T1D, is an autoimmune disease in which the body's immune cells—led by inflammatory macrophages—attack and destroy the beta cells of the pancreas that produce insulin.